Opportunistic Infections Caused by Serratia marcescens
Introduction
By [Brittany Currey]
Serratia marcescens, a rod-shaped gram-negative bacterium (0.5-0.8 µm in diameter and 0.9-2.0 µm in length), is a member of the Enterobacteriaceae family (4 11). It is a facultative anaerobe that can grow in the presence and absence of oxygen between 30°C and 37°C. It metabolizes by either respiratory or fermentative processes classifying it as a chemoorganotroph (4). Ubiquitous in nature, S. marcescens is found on dead organic material, while some inhabit soil, water, air, plants, animals, or food. In particular, food sources that provide a nutrient rich environment include starchy variants (11). The bacterium propels itself in these different environments using peritrichous flagellum (4).
Identifiable in ecological niches by their red pigment, prodigiosin (2-methyl-3-penty-6-methoxyprodigiosin), S marcescens can resemble blood (cite). Since this pigment is easily recognized in certain strains due to its red coloring, it has been extensively used as a biological marker (31). Also, prodigiosin has antibacterial, antifungal, antiprotozoan, and immunosuppressant activity. Environmental signals such as temperature, phosphate limitation, and medium components regulate prodigiosin production. Prodigiosin is not the only secreted product, many more include protease, nucleases, lipase, chitinase, the biosurfactant serrawettin, and hemolysin (29)
Although, S. marcescens was considered to be an innocuous, non-pathogenic organism, over the last two decades they have become an opportunist pathogen causing nosocomial infections (11). A broad range of hospital-acquired infections include respiratory tract infections, urinary tract infections (UTI), septicaemia, meningitis, pneumonia, conjunctivitis wound and eye infections, osteomyelitis, keratoconjunctivitis, keratitis, endophthalmitis and endocarditis (11, 28, 5, 14, 15). S. marcescens are also capable of causing disease in a diverse group of organisms including animals, coral, insects, and plants (11 and 8)
Many problems arise in treating nosocomial infections because of resistance to a variety of antibiotics, such as cephalosporins, aztreonam, imipenem, cefotaxime, and ceftazidime (16, 25). Therefore, novel treatment techniques are in need to eliminate infections without overuse of the antibiotic (29).
Rare cases of S. marcescens include nonhospital associated infections. These cases are linked to patients with immune deficiencies or chronic debilitating diseases. Human medicine, outside of hospital settings, can involve intravenous drug use that can also spread S. marcescens. Additionally, nonhospital acquired cases include patients with chronic, debilitating diseases (31).
Hydrophobicity
S. marcescens are pathogenic and virulent because of their ability to adhere to host epithelial surfaces. These organisms may possess pili that foster their adherence as well as an O-antigen that has a strong influence on the adhesion to both inert and biological surfaces (11). Other studies have shown that S. marcescens are capable of adhering to hydrocarbons and polystyrene allowing them infect hosts by cell-surface hydrophobicity (2).
Antibiotic Susceptibility
The external face of the outer membrane of S. marcescens is formed by lipopolysaccharide (LPS) which is responsible for the biological activity of an endotoxin in its ability to cause disease. The outer membrane that surrounds this gram negative bacterium cell protects it from toxic agents by slowing their penetration and hindering their access to the target sit. LPS is composed of parts that include the O-antigen, lipid A, and the core. (11).
Serratia marcescens can become resistant to β-lactamase via two methods. First, S. marcescens has been shown to decrease its outer-membrane permeability and second, this bacterium can synthesize β-lactamases by hydrolyzing carbapenems (11).
In several Enterobacteriaceae species, efflux by RND-type transporters is known to confer resistance to an antibiotic, tigecycline. Hornsey et al. (2010) examined tigecycline in Serratia marcescens clinical isolates and laboratory-selected mutants to investigate efflux by RND-type transporters. In gram negative bacteria, RND-type efflux systems usually have a cytoplasmic membrane pump, a periplasmic component, and an outer membrane channel. However, the outer membrane channels in S. marcescens are not fully understood. In this present study, up-regulation of endogenous SdeXY-HasF mediated efflux is associated with tigecycline resistance in S. marcescens (12).
Kumar and Worobee (2002) studied fluoroquinolone resistance of S. marcescens. They examined four fluoroquinolones (ofloxacin, ciprofloxacin, norfloxacin, and nalidixic acid) to determine the drug specificity of efflux. Western immunoblot experiments demonstrated the presence of at least two AcrA-like proteins in S. marcescens that resembled the periplasmic component of the pump. Thus, S. marcescens can become resistant to fluoroquinolones possibly by proton dependent efflux via RND pumps (16).
Diagnosis
Many cases of Serratia marcescens have been diagnosed by taking a biopsy of infected tissue, mucous, and blood. These samples were then grown in culture to see if a colony of S. marcescens appeared.
Treatment and Prevention
Infection control measures used to prevent the spread of Serratia marcescens outbreaks in NICUs and PICUs includes patient isolation, use of gloves and gowns, enforced hand disinfection, and correct use of antimicrobial substances (39,40).
Furthermore, effective measures of environmental cleaning depends highly on the availability of trained service personnel. Therefore, additional personnel should be recruited to help disinfect environmental hand contact surfaces and multiuse equipment (39).
Contaminated breast milk by S. marcescens may be prevented with proper handling, preparation, and storage in NICUs (39).
Reports have shown that if an outbreak of S. marcescens persists, some hospitals decided to close affected units to new admissions. Some closed beds to gain more space for infected patients. Although this method may prevent the spread of S. marcescens, a loss of income may result from a substantial decrease in patient numbers.(39)
Transmission in Hospitals
Serratia marcescens infections are known to be transmitted through hand-to-hand contact by medical personell. In this case, solutions used for medical purposes, catheterizations, and needle punctures can be contaminated (31). S. marcescens may also contaminate patients because they are known to survive and grow well on disinfectants, antiseptics, and in distilled water. In addition, S. marcescens have been found in de-ionized water isolated from blood bags (11).
Cases in Humans
![](/images/thumb/6/6d/Augmentation_Rhinoplasty.jpg/300px-Augmentation_Rhinoplasty.jpg)
Serratia marcescens. Image from:http://onlinelibrary.wiley.com/doi/10.1111/j.1524-4725.2010.01788.x/pdf
[[Image:Legulcers.jpg|thumb|300px|right|Figure 2:Top 0.5-cm protruding crusted papule on the tip on the nose infected with
Serratia marcescens. Image from:PMID: 18955204
First cases of nosocomial infections were recognized in humans in 1951 (31).
Dong Jin Ryu et al. (2010) presented a 26-year old woman who received augmentation rhinoplasty with a Gore-Tex implant. Twelve months following the initial plastic surgery, a second surgery was performed to fix the extrusion of the original implant with a silicone and cartilage implant. Two months later a folliculitis-like lesion formed on the tip of her nose. Signs of infection occurred when the lesion became tender and swelled enough to produce discharge. The lesion contained S. marcescens which was detected from a culture (Figur1). The lesion was treated with ceftazidime and ciprofloxacin, two antibiotics that produced significant effects on S. marcescens. The implant was later removed and the skin lesion healed three weeks later. Other Cutaneous infections caused by S. marcescens are uncommon but may be predisposed by immunocompromised conditions or pre-damaged skin (18). Langrock et al. (2008) presented a case in which a 73-year-old man contained multiple ulcers and painful nodules on the lower right leg as well as abscesses on the right malleolous lateralis. Skin cultures taken from the lesions were highly positive for S. marcescens. The skin lesions had appeared 4 weeks and neither topical nor oral antibiotic treatment with pencillin improved the lesions. Instead, topical therapy, repeated incision and draining of the abscesses, as well as the continuation of intravenous ertapenem improved skin lesions. The lesions improved gradually after 10 days of treatment and infection ceased completely, leaving hyperpigmented scars on the lower right leg (Figure 2).
Five cases have been reported of Necrotizing fasciitis (NF) which infects soft tissues that spreads along fascia lines. Four of the five cases had lower extremity NF while one case involved an immunocompetent 2-year-old-who developed cervical NF infecting fascia planes of the head and neck (37). This patient with cervical NF was treated with serial debridements with irrigation of 3% hydrogen peroxide that was effective at removing necrotic tissue without need for external incisions. Unfornately, this patient was in an intensive care unit for a prolonged period of time due to sedation to tolerate wound packing and rapidly succumbed to the infection (37).
Several outbreaks of Serratia marcescens have been found in neonatal and pediatric intensive care units (NICU, PICU) throughout the world. Voelz et al. (2010) reported 27 studies in which 34 outbreaks of S. marcescens resulted. The Department of Hospital Epidemiology and Infection Control at the Johns Hopkins Hospital in Baltimore, Maryland, detected an outbreak of multidrug–resistant (MDR) S. marcescens in a 36-bed NICU. The investigation took place from October 2004 through February 2005 in which one-third of the neonates hospitalized became infected or colonized the MDR bacterium. The strain of S. marcescens was resistant to a majority of commonly prescribed antimicrobial agents. The epidemiologic report did not identify environmental or healthcare worker hands as the source of contamination because the case-control study was limited by a small sample size. However, individuals with low birth rates have previously been found as a risk factor for S. marcescens infection among neonates. Also, transmission of MDR S. marcescens was thought to be acquired by the location within the NICU. Here, reports show that the majority of the patients in pod 1 had acquired the organism, implying that there may have been an undetected environmental source or vector of transmission. The acquisition of the infection could also have been due to overcrowding of pod 1 where sufficient space was not provided between beds and improper hand hygiene (26). Overall, Maragakis et al. (2008) believe that the organism was spread by transient carriage on the hands of healthcare personnel or on contaminated endotracheal respiratory care equipment.
In Vienna, Austria, another outbreak of S. marcescens was detected in a NICU between October 1, 2000, and February 28, 2001. After eight patients were found to be colonized with the bacterium, the NICU was closed on December 27 for 10 days; to implement infection control measures and thoroughly disinfect the care unit. The primary case had septicemia with S. marcescens and after analysis of risk factors this neonate was suspected to have acquired the bacterium from his mother, who was treated 9 days with cefuroxime as a prophylactic treatment to avoid chorioamnionitis (inflammation of fetus) and intrauterine infection of the neonate after premature rupture of the membrane (1). A second case located next to the primary case also was infected with S. marcescens with conjunctivitis. All strains of S. marcescens were biologically identical, containing no pigmentation and were sensitive to imipenem S, cefotaxin R, cefpirom S, gentamicin S, amikacin S, trimethoprim S, and ciprofloxacin S. However, two cases were identified after the unit was closed and differed from the previous S. marcescens strains due to their red pigmentation and susceptibility of all antibiotics. To summarize, affected neonates may have spread the infection via horizontal transmission by healthcare workers and mothers may have been exposed to antibiotics that caused overgrowth of resistant organisms. This rapid spreading infection was halted at an early stage with aggressive infection control measures(1).
Cases in Animals
Perez et al. (2011) reports nonhospital-acquired S. marcescens bacteria in a 12 year old male Dalmatian dog. The owners observed symptoms of a head tilt to the right, falling to the left, and nystagmus (involuntary eye movements). The primary veterinarian diagnosed the dog with canine idiopathic vestibular disease which affects neurological pathways. Five days later, the vestibular signs continued in the untreated dog along with vomiting. The dog was re-evaluated for a heart murmur and fever and referred to the Veterinary Teaching Hospital, College of Veterinary Medicine at North Carolina State University for additional diagnostic evaluation. An echocardiography found lesions on the aortic valve causing abnormal growth which was diagnosed as aortic valve endocarditis. Blood samples collected from different anatomical sites resulted in negative detection of Anaplasma spp., Borrelia burgdorferi, Ehrlichia canis antibodies, and Diofilaria immitis antigen. Subsequently, the dog was treated with amplicillin, sulbactam, and doxycycline antibiotics. In conjunction, famotidine and metoclopramide were administerd for the vomiting. Despite aggressive therapy for congestive heart failure, the dog failed to respond to antimicrobials, developed opisthotonus (body frame forms a reverse bow due to severe spasms and hyperextension), and died within six hours after admission. Necropsy confirmed aortic valve endocarditis and were consistent with heart failure and septicemia. The blood samples returned in less than 12 hours, yielding a heavy growth of a pure culture of S. marcescens. This bacterium was resistant to the treatment antibiotics, however; it was susceptible to quinolones, third generation cephalosporins, imipenem, and aminoglycosides. This case of S. marcencens accumulated rapidly within the dog who was not hospitalized prior to infection. Thus, the dog acquired this infection in a community-related setting (31).
Many other animal related cases have been described in hospital practices. For instance, six dogs were infected and this was the first documentation of nosocomial Serratia spp septicemia in 1973. Prior to Serratia spp septicemia diagnosis, all six dogs were previously diagnosed with debilitating diseases and later developed a fever under intensive hospital care with an indwelling jugular catheter (31, 41). Although, the source of infection was not determined in these six cases, subsequent studies found that the high prevalence of S. marcescens in hospital related cases were due to contaminated benzalkonium chloride sponge pots used as an antiseptic.
A study from South Africa isolated 22 IV catheters from 100 dogs with parvoviral enteritis. Only 2 catheters tested positive for S marcescens (22, 31). In another case, a Doberman Pinscher underwent a tooth extraction and later developed fatal necrotizing fasciitis in association with S. marcescens. It was suggested that the bacteria was transmitted in the oral surgery by skin contamination at injection sites (31, 33).
During the winter of 1952, a herd of twenty-four milking cattle were housed in a conventional type barn, where a mild outbreak of mastitis due to haemolytic Staphylococcus aureus occurred. In this community setting, they also isolated Serratia marcescens from incubated milk. The cows’ symptoms included swelling of the gland and visibly abnormal milk clots. The organism was found to be susceptible to four or five grams of neomycin and was eliminated over a three day period (3).
Conclusion
Overall text length at least 3,000 words, with at least 3 figures.
References
1.Assadian, Ojan, Berger, Angelika, Aspöck, Christoph, Mustafa, Stefan, Kohlauser, Christina, Hirschl, Alexander. 2002. Nosocomial Outbreak of Serratia Marcescens in a Neonatal Intensive Care Unit. Infection control and Hospital Epidemiology 23: 457-463.
2.Bar-Ness, Ronit, and Rosenberg, Mel. 1989. Putative Role of 70 kDa Outer-surface Protein in Promoting Cell-surface Hydrophobicity of Serratia marcescens RZ. General Microbiology 135: 2277-2281.
3.Barnum, D.A., Thackeray, E.L., and Fish, N.A. 1958. An Outbreak of Mastitis Caused by Serratia Marcescens. Canadian Journal of Comparative Medicine 22: 392-395.
4.Breed, R.S., Murray, E.G.D., and Smith, N.R. 1957.Bergey’s Manual of Determinative Bacteriology. 9th edition. Page 187.
5.Castelli, Maria E., Fedrigo, Griselda V., Clementín, Ana L., Ielmini, M. Verónica, Feldman, Mario F., and Véscovi, Eleonora G. 2008. Enterobacterial Common Antigen Integrity Is a Checkpoint for Flagellar Biogenesis in Serratia marcescens. Bacteriology 190: 213-220.
6.Chen, Jing, Kuroda, Teruo, Huda, Nazmul, Mizushima, Tohru, and Tsuchiya, Tomofusa. 2003. An RND-type multidrug efflux pump SdeXY from Serratia marcescens. Antimicrobial Chemotherapy 52: 176-179.
7.Clayton, Edwin, and Graevenitz, Alexander V. 1966. Nonpigmented Serratia marcescens. American Medical Association 197: 111-116.
8.Coulthurst, Sarah J., Williamson, Neil R., Harris, Abigail K.P., Spring, David R., and Salmond, George P.C. 2006. Metabolic and regulatory engineering of Serratia marcescens: mimicking phage-mediated horizontal acquisition of antibiotic biosynthesis and quorum-sensing capacities. Microbiology 152: 1899-1911.
9.Fineran, Peter C., Williamson, Neil R., Lilley, Kathryn S., and Salmond, George P.C. 2007. Virulence and Prodigiosin Antibiotic Biosynthesis in Serratia Are Regulated Pleiotropically by the GGDEF/EAL Domain Protein, PigX. Bacteriology 189: 7653-7662.
10.Haddix, Pryce L., Jones, Sarah, Patel, Pratik, Burnham, Sarah, Knights, Kaori, Powell, Joan N. and LaForm, Amber. 2008. Kinetic Analysis of Growth Rate, ATP, and Pigmentation Suggests an Energy-Spilling Function for the Prodigiosin of Serratia marcescens. Bacteriology 190: 7453-7463.
11.Hejazi, A. and Falkiner, F.R. 1997. Serratia marcescens. Medical Microbiology 46: 903-912.
12.Hornsey, Michael, Ellington, Matthew J., Doumith, Michel, Hudson, Sue, Livermore, David M., and Woodford, Neil. 2010. Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome. Antimicrobial Chemotherapy 65: 479-482.
13.Kalivoda, Eric J., Stella, Nicholas A., O’Dee, Dawn M., Nau, Gerard J., and Shanks, Robert M.Q. 2008. The Cyclic AMP-Dependent Catabolite Repression System of Serratia marcescens Mediates Biofilm Formation through Regulation of Type 1 Fimbriae. Applied and Environmental Microbiology 74: 3461-3470.
14.Kida, Yutaka, Inoue, Hiroyoshi, Shimizu, Takashi, and Kuwano, Koichi. 2007. Serratia marcescens Serralysin Induces Inflammatory Responses through Protease-Activated Receptor 2. Infection and Immunity 75: 164-174.
15.Koh, Kai S., Lam, Kin W., Alhede, Morten, Queck, Shu Y., Labbate, Maurizio, Kjelleberg, Staffan, and Rice, Scott A. 2007. Phenotypic Diversification and Adaptation of Serratia marcescens MG1 Biofilm-Derived Morphotypes. Bacteriology 189: 119-130.
16.Kumar, Ayush, and Worobee, Elizabeth A. 2002. Fluoroquinolone resistance of Serratia marcescens: involvement of a proton gradient-dependent efflux pump. Antimicrobial Chemotherapy 50: 593-596.
17.Labbate, Maurizio, Zhu, Hua, Thung, Leena, Bandara, Rani, Larsen, Martin R., Willcox, Mark D.P., Givskov, Michael, Rice, Scott A., and Kjelleberg, Staffan. 2007. Quorum-Sensing Regulation of Adhesion in Serratia marcescens MG1 Is Suface Dependent. Bacteriology 189: 3461-3470.
18.Langrock, Marie-Lousie, Linde, Hans-Jörg, Landthaler, Michael, and Karrer, Sigrid. 2008. Leg ulcers and abscesses caused by Serratia marcescens. Eur J Dermatol 18: 705-707. PMID: 18955204
19.Li, Bin, Yu, Rongrong, Liu, Baoping, Tang, Qiaomei, Zhang, Guoqing, Wang, Yanli, Xie, Guanlin, Sun, Guochang. 2011. Characterization and comparison of Serratia marcescens isolated from edible cactus and from silkworm for virulence potential and chitosan susceptibility. Microbiology 42: 96-104.
20.Li, B., Xu, L.H., Chen, X.L., Lui, B.P., Zhu, B., Fang, Y., Qui, W., and Xie, G.L. 2009. Effect of chitosan solution on the bacterial septicemia disease of Bombyx mori (Lepidoptera: Bombycidae) caused by Serratia marcescens. Appl. Entomol. Zool. 45: 145-152.
21.Lima, KV, Carvalho,RG, Carneiro, IC, Lima, JL, Sousa Cde, O., Loureiro, EC, Sá, LL, and Bastos, FC. I 2011. Outbreak of neonatal infection by an endemic clone of Serratia marcescens. Revista da Sociedade Brasilleira de Medicina Tropical 44: 106-109.
22.Lobetti RG, Joubert KE, Picard J, et al. 2002. Bacterial colonization of intravenous catheters in youngs dogs suspected to have parvoviral enteritis. Am Vet Med Assoc 220: 1321-1324.
23.Lu, Chia-Chen, Lai, Hsin-Chih, Hsieh, Shang-Chen, and Chen, Jan-Kan. 2008. Resveratrol ameliorates Serratia marcescens- induced acute pneumonia in rats. Leukocyte Biology 83: 1028-1037.
24.Makimura, Yutaka, Asai, Yasuyuki, Sugiyama, Akiko, and Ogawa, Tomohiko. 2007. Chemical structure and imunobiological activity of lipid A from Serratia marcescens LPS. Medical Microbiology 56: 1440-1446.
25.Mammeri, Hedi, Poirel, Laurent, Bemer, Pascal, Drugeon, Henri, and Nordmann, Patrice. 2004. Resistance to Cefepime and Cefpirome Due to a 4-Amino-Acid Deletion in the Chromosome-Encoded AmpC β-Lactamase of a Serratia marcescens Clinical Isolate. Antimicrobial Agents and Chemotherapy 48: 716-720.
26.Maragakis, Lisa L., Winkler, Amy, Tucker, Margaret G., Cosgrove, Sara E., Ross, Tracy, Lawson, Edward, Carroll, Karen C., Perl, Trish M. 2008. Outbreak of Multidrug-Resistant Serratia marcescens Infection in a Neonatal Intensive Care Unit. Infection Control and Hospital Epidemiology 29: 418-423.
27.Maseda, Hideaki, Hashida, Yumiko, Konaka, Rumi, Shirai, Akihiro, and Kourai, Hiroki. 2009. Mutational Upregulation of a Resistance-Nodulation-Cell Division-Type Multidrug Efflux Pump, SdeAB, upon Exposure to a Biocide, Cetylpyridinium Chloride, and Antibiotic Resistance in Serratia Marcescens. Antimicrobial Agents and Chemotherapy 53: 5230-5235.
28.Matsuo, Taira, Chen, Jing, Minato, Yusuke, Ogawa, Wakano, Mizushima, Tohru, Kuroda, Teruo, and Tscuhiya, Tomofusa. 2008. SmdAB, a Heterodimeric ABC-Type Multidrug Efflux Pump, in Serratia marcescens. Bacteriology 190: 648-654.
29.Morohoshi, Tomohiro, Shiono, Toshitaka, Takidouchi, Kiyomi, Kato, Masashi, Kato, Norihiro, Kato, Junichi, and Ikeda, Tsukasa. 2007. Inhibition of Quorum Sensing in Serratia marcescens AS-1 by Synthetic Analogs of N-Acylhomoserine Lactone. Applied and Environmental Microbiology 73: 6339-6344.
30.Nicasio, Anthony M., Quintiliani Jr, Richard, DeRyke, C Andrew, Kuti, Joseph L., Nicolau, David P. 2007. Treatment of Serratia marcescens Meningitis with Prolonged Infusion of Meropenem. The Annals of Pharmacotherapy 41: 1077-1081.
31.Perez, Cristina, Fujii, Yoko, Fauls, Megan, Hummel, James, and Breitschwerdt, Edward. 2011. Fatal Aortic Endocarditis Associated with Community-Acquired Serratia marcescens Infection in a Dog. American Animal Hospital Association 47: 133-137.
32.Petty, Nicola K., Foulds, Ian J., Pradel, Elizabeth, Ewbank, Jonathan J., and Salmond George P.C. 2006. A generalized transducing phage (ϕIF3) for the genomically sequenced Serratia marcescens strain DB11: a tool for functional genomics of an opportunistic human pathogen. Microbiology 152: 1701-1708.
33.Plavec T, Zdovc I, Juntes P, et al. 2002. Necrotizing fasciitis caused by Serratia marcescens after tooth extraction in a Doberman Pinscher: a case report. Veterinarni Medicina 53: 629-635.
34.Quarles, John M., Belding, Ralph C., Beaman Cabrera, Teofila, and Gerhardt, Philipp. 1974. Hemodialysis Culture of Serratia marcescens in a Goat-Artificial Kidney-Fermentor System. Infection and Immunity 9: 550-558.
35.Rabea, Entsar I., Badaway, Mohamed E.T., Stevens, Christian V.m Smagghe, Guy,and Steurbaut, Walter. 2003. Chitosan as Antimicrobial agent: Applications and Mode of Action.Biomacromolecules 4: 1457-1465. http://pubs.acs.org/doi/pdf/10.1021/bm034130m
36.Ryu, Dong Jin, Oh, Sang Ho, Choi, Yoon Jin, and Lee, Ju Hee. 2010. A Case of Serratia marcescens After Augmentation Rhinoplasy. American Society for Dermatologic Surgery 36: 2079-2081.
37.Statham, Melissa M., Vohra, Amit, Mehta, Deepak K., Baker, Troy, Sarlay, Robert, and Rutter, Michael J. 2009. Serratia marcescens causing cervical necrotizing oropharyngitis. International Jouranl of Pediatric Otorhinolaryngology 73: 467-473.
38.Trilla, A. 1994. Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 20: S1-S4.
39.Voelz, Alexander, Müller, Andreas, Gillen, Julia, Le, Celine, Dresbach, Till, Engelhart, Steffen, Exner, Martin, Bates, Christine J., and Simon, Arne. 2010. Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: Clinical aspects, risk factors and management. Int. J. Hyg. Environ. Health 213: 79-87.
40.Vonberg, Weitzel-Kage, Behnke, and Gastmeier. 2011. Worldwide Outbreak Database: the largest collection of nosocomial outbreaks. Infection 39: 29-34.
41.Wilkins RJ. 1973. Serratia marcescens septicaemia in the dog. Small Anim Pract 14: 205-15.
Edited by student of Joan Slonczewski for BIOL 238 Microbiology, 2011, Kenyon College.